“Good things take time” Allogeneic Treg do not prevent their own rejection in immunocompetent hosts - HLA matching or HLA editing required for optional function! A beautiful collaboration with Fadi Issa & Joanna Hester’s team @ox.ac.uk. @dlwagnerlabs.bsky.social

Waggoner Lab@labwaggoner.bsky.social · 10mo ago

HLA matching or CRISPR editing HLA-I/II enables engraftment & function of allo human Treg therapy in a humanized mouse transplantation model @natcomms.nature.com @dlwagner.bsky.social @bcmhouston.bsky.social www.nature.com/articles/s41...

@dlwagnerlabs.bsky.social on tour! 🌍🇩🇪🇺🇸 We had a great time at the Annual Congress of the European Society for Gene and Cell Therapy #ESGCT2025 in Sevilla. 🇪🇸 Super proud of everyone who presented their projects & grateful for working with this amazing team: science and good vibes! 🧬🧪💙

Our team is on their way to the ESGCT conference 2025! Excited for this upcoming week full of science, talks, and inspiring discussions with the cell & gene therapy community! Starting with the HDR workshop - talks by Isabell (‘one-pot’ PASTA) & Viktor (BEKI) + posters by Ana, Lily, Jonas and Laura

You like engineering T cells, but you are missing the right flavor? Check out 'one-pot' PASTA recipe 🔥🍝: www.biorxiv.org/content/10.1101/2025.09.10.675267v1 We combined a unique mix of CRISPR knock-in with serine integrases for easy-to-adopt 𝐏rogrammable 𝐀nd 𝐒ite-specific 𝐓ransgene 𝐀ddition 🧪

Versatile and efficient non-viral integration of large transgenes in human T cells via CRISPR knock-in and engineered integrases

Current gene transfer methods often lack the precision, versatility, or efficiency when integrating large transgenes, limiting the ability to engineer therapeutic T-cells with more complex payloads. H...

biorxiv.org

Lab History pt. 6 (2025) For non-viral CAR-T cell generation with Cas12a, what is BETTER THAN DOUBLE-STRANDED DNA ? www.cell.com/molecular-th...

Lab History pt. 5 (2025) What is the best Knock-in strategy to make CAR-Tregs?? our answer is published in Molecular Therapy 🔗 www.cell.com/molecular-th...

Lab History pt. 4 (2024) What could be BETTER THAN TRAC KNOCK-IN ?? CD3Z-CAR KI story, published in Blood pmc.ncbi.nlm.nih.gov/articles/PMC...

Lab History pt. 3 (2023) Ultra-depletion of TCR+ cells from allogeneic CAR T cells to prevent GvHD.... LOG-FOLD BETTER THAN MACS!!! HOW? => Addition of short-lived TCR-specific CAR NK-92 cells during expansion. Published in Blood Advances 🔗 ashpublications.org/bloodadvance...

Lab History pt. 2 (2023) Single-step, complex non-viral CAR-T engineering: Cas12a for TRAC KI + nCas9 base editors for multiplex-KO. => Using orthogonal CRISPR systems for KI and KO ↓ translocations to <0.1%. Published in Genome Biology. 🔗 link.springer.com/article/10.1...

Lab History pt. 1 2022 – 🚨 Our first paper is out! 🚨 virus-free CAR knock-in to TRAC locus of primary human T cells with CRISPR-HDR. ➡️ >50% TRAC CD19-CAR T cells through pharmacological modulation 🧬 A key step toward scalable, non-viral CAR-T cell therapies. DOI: 10.1016/j.omtm.2022.03.018